

IND approval and securing IMP batch for GENA-104A16, an immune checkpoint inhibitor targeting CNTN4

Genome & Company
GENOME & CO

ONCOLOGY	Non-Clinical
Product Type	Biologic-Antibody Humanized monoclonal antibody of IgG4 (S228P) isotype
Indication	Solid tumor
Target	CNTN4 (Contactin-4)
MoA(Mechanism of Action)	GENA-104A16 binds to the CNTN-4, novel inhibitory immune checkpoint, obstructing communication between CNTN4 and its binding partner APP expressed on T cells, helping to restore T-cell function.
Competitiveness	Targeting novel inhibitory immune checkpoints can be a new opportunity for patients with cancers who do not benefit from targeting PD-1, PD-L1, and CTLA-4.
Development Stage	Non-Clinical
Route of Administration	Intravenous infusion